Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BYON4228 with rituximab in relapsed/refractory CD20+ B-cell NHL
NCT05737628Phase 1Active, not recruiting
- Sponsor
- Byondis
- Start
- Mar 2024
- Primary completion
- Feb 2026
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 4
01
Overview
Phase 1, open-label, single-arm trial of BYON4228 in non-Hodgkin lymphoma (NHL), sponsored by Byondis. Primary endpoint: Dose-Limiting Toxicities at 28 days. Started Mar 2024; status: active, not recruiting.
02
Drugs
BYON4228
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT05737628.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05737628.